• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

4.670 -0.510 (-9.85%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,116,654
Open 5.120
Bid (Size) 4.690 (500)
Ask (Size) 5.000 (200)
Prev. Close 5.180
Today's Range 4.650 - 5.205
52wk Range 1.140 - 7.200
Shares Outstanding 58,576,350
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Keep an eye on the top gainers and losers in Tuesday's session. ↗
December 16, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
These stocks are moving in today's session ↗
December 16, 2025
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill

Performance

YTD
N/A
N/A
1 Month
-4.3%
-4.3%
3 Month
-15.2%
-15.2%
6 Month
+7.4%
+7.4%
1 Year
-14.3%
-14.3%

More News

Read More
News headline image
Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision? ↗
December 16, 2025
Via Stocktwits
News headline image
Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease
December 15, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast
November 13, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
November 11, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET
November 06, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra’s Experimental Drug Shows Promising Results In Mid-Stage Alcohol Hepatitis Trial ↗
October 28, 2025
Via Stocktwits
News headline image
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules
October 28, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals ↗
October 10, 2025
Via Benzinga
News headline image
4 Biotech Stocks Seeing Explosive Momentum Gains ↗
October 07, 2025
Via Benzinga
Topics ETFs Stocks
News headline image
Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 03, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma
August 28, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa
August 19, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
August 06, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa
July 24, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
July 17, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma
June 26, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
June 17, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference
May 29, 2025
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
May 18, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm
May 14, 2025
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDX
May 13, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
May 09, 2025
From Pomerantz LLP
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm
May 07, 2025
From Bragar Eagel & Squire
Via GlobeNewswire

Frequently Asked Questions

Is Aldeyra Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aldeyra Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aldeyra Therapeutics, Inc. - Common Stock trade on?
Aldeyra Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aldeyra Therapeutics, Inc. - Common Stock?
The ticker symbol for Aldeyra Therapeutics, Inc. - Common Stock is ALDX on the Nasdaq Stock Market
What is the current price of Aldeyra Therapeutics, Inc. - Common Stock?
The current price of Aldeyra Therapeutics, Inc. - Common Stock is 4.670
When was Aldeyra Therapeutics, Inc. - Common Stock last traded?
The last trade of Aldeyra Therapeutics, Inc. - Common Stock was at 01/02/26 04:00 PM ET
What is the market capitalization of Aldeyra Therapeutics, Inc. - Common Stock?
The market capitalization of Aldeyra Therapeutics, Inc. - Common Stock is 273.55M
How many shares of Aldeyra Therapeutics, Inc. - Common Stock are outstanding?
Aldeyra Therapeutics, Inc. - Common Stock has 274M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap